ABSTRACT
To evaluate the clinical relevance of testing pituitary-ovarian responses in patients suffering from polycystic ovary syndrome (PCOS) with the GnRH agonist nafarelin, a 1.2-mg dose of nafarelin was given intranasally to 19 women with PCOS and 15 healthy premenopausal women. The subsequent analysis of steroids in both serum and urine during the test was carried out at several time points for up to 24 h. Serum levels of 17a-hydroxyprogesterone were elevated at all time points of the test in PCOS patients US. controls [at baseline, 3.5?0.2vs.
1.8t0.1nmol/L(P<0.001);at24h,9.9~0.9us.4.9~ 0.3 nmoVL (P < O.OOl)]. Basal levels of androstenedione were higher in the patient group, but there was no significant change during the test in either group. Serum testosterone levels were also found to differ in PCOS patients compared with the control values at baseline (2.2 ? 0.2 us. 1.5 2 0.1 nmol/L; P < 0.05) and after nafarelin treatment (at 24 h, 3.2 -t 0.4 us. 1.8 2 0.2 nmol/L; P < 0.05). Serum estradiol levels rose significantly in both groups during the test; the posttest levels were significantly higher in PCOS than in controls. The PCOS patients displayed a significant increase in androgen and gestagen metabolites as well as in glucocorticoid metabolites excreted in the urine during the 24 h. In the control subjects, except for 17a-hydroxypregnanolone, which rose significantly, none of the urinary steroids investigated showed relevant changes during the nafarelin test. The posttest excretion of allo-tetrahydrocortisol(1.4 + 0.2 US. 0.3 5 0.1 pmol/g creatinine; P < 0.001) and the increase in 17a-hydroxypregnanolone excretion (1.4 + 0.2 us. 0.3 -t 0.1 Fmol/g creatinine; P < 0.001) were distinctly higher in PCOS patients than in the controls; the diagnostic sensitivity of the combination of both parameters was 89% at a 93% specificity. A: androstenedione (androst-4-ene-3,17-dione); AD: androstanediol (3a,l7P-dihydroxy-5c-androstane); ADG: androstane-diol glucuronide (3ol,l7P-dihydroxy-5cY-androstane 3-glucuronide); ADT: androsterone (3cu-hydroxy-5a-androstan-17-one); ADTG: androsterone glucuronide (3a-hydroxy-5a-androstan-17.one 3-glucuronide); CORT: cortolone (3o1,17a,20&,21-tetrahydroxy-5P-pregan-ll-one);
PCORT: p-cortolone (3a,17a,20a,21-tetrahydroxy-5P-pregnan-ll-one); DHEA: dehydroepiandrosterone (3/3-hydroxyandrost-5-en-17-one); DHEAS: dehydroepiandrosterone-sulfate (3P-hydroxyandrost-5-en-17-one 3-sulfate); E: cortisone (17a,21-dihydroxypregn-4-ene-3, 11,20-trione (3a, l7a, THF: tetrahydrocortisol (3a, ll&17a, ; aTHF: allo-tetrahydrocortisol (3a,llp,17a,21-tetrahydroxy-5a-pregan-20-one);
THS: tetrahydro-ll-deoxyxortisol (3a,17a, 21-trihydroxy-5P-pregnan-20-one).
The etiology of the disorder is still a subject of controversy. There are lines of evidence suggesting that PCOS is a form of functional ovarian hyperandrogenism, triggered by gonadotropin-dependent mechanisms (6, 7). One explanation of this phenomenon is the estrone hypothesis (8,9), according to which permanent hyperestronemia is thought to sensitize the pituitary (9, 10) and cause an increase in LH secretion. As a result, thecal-interstitial cells are stimulated to hyperplasia, leading to an excess secretion of androstenedione (A) and other androgens.
An elevation in unbound or free estradiol (E2) has also been suggested to be a contributory factor (11). These and other theories are not mutually exclusive. More recently, defects in different enzyme systems regulating the steroid pathway have been thought to initialize the pathophysiological conditions for PCOS. One of the underlying defects is thought to be an increase in the activity of skin and hepatic 5a-reductase (12, 13), resulting in an augmented conversion of testosterone (T) to dihydrotestosterone (14). In gas chromatography steroid profiles, this results in higher ratios of 5o-tetrahydrocortisol (aTHF)/SPtetrahydrocortisol (THF) and 5a-androsterone (5aADT)/ 5P-etio-cholanolone (5PET) in urine (14 
Nafarelin test
The nafarelin test was performed in a modification of the original protocol (6); GnRHa was administered intranasally instead of SC (37). To each study subject, six sniffs (three sniffs in each nostril) of 0.23 mg nafarelin acetate (Synarela, Syntex Pharma, Aachen, Germany), equivalent to a total of 1.20 mg nafarelin, were administrated. The bioavailability of intranasally applied nafarelin is 3% (17, 18) , and the serum half-life is 4.4 h. All subjects were admitted to the ward on the morning of the test between 0800-1000 h between the third to sixth day of the menstrual cycle, if present. All subjects collected a pretest 24-h urine sample. Blood samples were drawn 15 min before and 0, 2,4, and 24 h after nafarelin administration, and a second 24-h urine sample was collected with the time set from time zero. All blood and urine specimens were centrifuged at 2000 X g and frozen at -20 C until analyzed. No serious side-effects were observed during our study. Folsom, CA). The carrier gas was helium at a flow rate of 2.2 mL/min.
The injector temperature was set at 290 C; the column temperature isothermal was 150 C for 5 min, then 150-300 C with a heating rate of 2 C/min; the flame ionization detector temperature was 320 C; the splitting ratio was 1:20. A Mega-Integrator D-2500 (Merck, Darmstadt, Germany) was used as system controller. The reagents /3-glucuronidase and arylsulfatase (type H-2, crude solution from Helix porn&n), as well as the reference steroid compounds, and the hydrocarbon calibrators C,, (n-docosane), C,, (n-tetracosane), and C,, (?I-dotriacontane) were obtained from Sigma (Deisenhofen, Germany and twice with 5 mL water. The cartridge was eluted twice with I-mL portions of methanol, the eluate was evaporated at 50 C under vacuum, and the residue was dissolved in 100 PL methanol, 10 mL water, 1 mL 0.2 mol/L sodium acetate buffer (pH 5.2), and 100 PL P-glucuronidaselarylsulfatase solution (100,000 U/mL glucuronidase and 5,000 U/mL sulfatase; U = modified Fishman unit). Hydrolysis was then performed at 55 C for 2 h (39). The hydrolyzed residue was adsorbed again on a Sep-Pak C,, cartridge. One gram of anhydrous sodium sulfate was placed on the top of a NH, cartridge, and the C,, cartridge was connected on the top of this (40). The cartridges were eluted with two portions of 1.5 mL ethyl acetate-methanol (9:1, vol/vol).
Twenty micrograms each of C,,, C,,, and C,, hydrocarbons dissolved in 100 ILL II-hexane were added as calibrators for the retention indices to the eluate, and the solvents were then evaporated.
The derivatization was performed with 50 PL MSTFA and 100 PL pyridine containing 10 mg sodium acetate at 70 C for 24 h (41). Two microliters were used for GC analysis. This procedure of derivatization fully converts 17.keto groups into enol-trimethylsilyl ethers and hydroxy groups into trimethylsilyl derivatives, with the exception of Il-hydroxy and 1 I-keto groups.
Peak identification: By coinjection of authentic steroid compounds (extracted in parallel with the urine samples), the methylene units of the relevant steroids were calculated and used to identify the peaks. Confirmation of steroid identity, when necessary, was assessed by GC/mass spectrometry techniques. Peak quantification:
The steroid concentrations found in urine were calculated from peak area ratios related to the internal standard 3PET and expressed as micromoles of steroid per g creatinine in the respective urines.
A typical urinary steroid profile of a PCOS patient performed using the GC technique applied is shown in Fig. 1 . The overall interassay CV for all steroids measured was 4.5% (n = 6). 
Statistical analysis

Results
Serum levels of gonadotropins and steroids
The intranasal application of nafarelin resulted in a significant rise in serum LH and FSH levels (P < 0.001) in all women (PCOS patients and controls). For both gonadotropins, peak levels occurred after 4 h. Two patients showed increasing concentrations of LH or FSH even up to the last measurement at 24 h. In all women tested with nafarelin, the levels of LH and FSH at 24 h were higher than the respective basal pretest values. As shown in Table 2 , there were no significant differences between controls and PCOS patients in basal or stimulated LH or FSH levels. The LH/FSH ratio, however, was significantly higher in PCOS patients than in controls 24 h after GnRHa application (2.6 + 0.4 us. 1.6 '-0.1; P < 0.05).
Serum 17HPROG levels were elevated at all time points in PCOS patients compared with those in control subjects (P < 0.001). The baseline level of 17HPROG in PCOS patients was 3.5 2 0.2 compared to 1.8 + 0.1 nmol/L in the controls. In both groups, 17HPROG and its precursor, PROG, rose significantly during the test (P < 0.001; Table 2 and Fig. 2) ; the rates of increase in 17HPROG were similar in the two groups. At baseline, no difference was seen in the serum levels of PROG between the groups. Basal serum A levels were higher in PCOS patients than in controls (9.2 ? 0.3 VS. 6.2 + 0.5 nmol/L; P < 0.001). Neither the PCOS patients nor the controls exhibited a significant change in A levels during the test (Table 2 ). Similar to those of A, the basal serum levels of T were elevated in PCOS patients compared to the control values (2.2 + 0.2 US. 1.5 + 0.1 nmol/L; P < 0.05). Only in the PCOS patients was a significant rise in T observed during the test (at 24 h, 3.2 + 0.4 VS. 1.8 -t 0.2 nmol/L; P < 0.01). SHBG levels were lower in the PCOS patients than in the controls (data not shown). Therefore, the FAI levels were significantly higher in the PCOS patients, both basally and during the course of the 
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Serum F levels were higher in PCOS patients than controls at all time points (P < 0.01 at 0 and 24 h; P < 0.05 at 2 and 4 h). Due to the dynamic fluctuations in serum F during the day, the Friedman test was not applied to the different values of the two groups.
Levels of steroids in the 24-h urine samples
The results of the steroid profiles for both the PCOS patients and the controls during the nafarelin test are shown in Table 3 for significances). With respect to the differences observed between the patients and controls, the following parameters were higher at baseline: THE (P < 0.05), aTHF (P < 0.5), ADT/ET ratio (P < 0.05), and aTHF/THF ratio (P < 0.01). Ratios of ADT/ET and aTHF/ THF may be considered to be indirect measures of 5a-reductase activity.
After stimulation, the following parameters were higher in PCOS patients: ADT (P < O.Ol), 17HPREG (P < 0.05), PT (P < 0.05), THE (P < 0.05), THF (P < 0.05), aTHF (P < O.OOl), ADT/ET ratio (P < 0.05), corticoid sum (= CORT + /3CORT + THE + THF + aTHF) (P < 0.05), and free F (P < 0.05). Significant stronger increases over 24 h were found in urine from PCOS patients for ADT, ET, 17HPREG, PT, CORT, THF, and free F All parameters, except ratios and F, are given as micromoles per g creatinine; F is given as nanomoles per g creatinine. Cart.-sum, CORT + pCORT + THE + THF + aTHF. a P < 0.05, pre-US. postnafarelin (Wilcoxon test). ' P < 0.01, PCOS us. controls (Mann-Whitney test). c P < 0.01, pre-US. postnafarelin (Wilcoxon test). d P < 0.05, PCOS US. controls (Mann-Whitney test). ' P < 0.001, PCOS us. controls (Mann-Whitney test). f P < 0.001, pre-US. postnafarelin (Wilcoxon test). compared to those in the healthy controls. The most prominent differences between the two groups were found for the increase in 17HPREG levels (1.4 + 0.2 US. 0.3 -t 0.1 pmol/g creatinine; P < 0.001) and the poststimulation value of aTHF (3.4 2 0.4 US. 1.8 + 0.1 pmollg creatinine; P < O.OOl), as shown in Fig. 3 . Tetrahydro-1 I-deoxycortisol (THS), a derivative of the F precursor ll-deoxycortisol, was found only in low concentrations in both patients and controls, and significant differences or changes could not be determined.
In contrast to PT (a derivative of 17HPROG), no significant differences or changes were seen in pregnanediol (I'D) levels, which is a product of PROG.
The ratio of THE/THF, an indicator of the 1lPHSDH activity and similar to the ratio of the ll-0x0/11-hydroxy metabolites of F was significantly different (P < 0.05) in PCOS patients us. controls at baseline, whereas in the course of the test, the PCOS patients showed a significant decrease (P < 0.05).
Calculation of sensitivities and specificities of several analytes in the course of the test revealed that, based on 93% specificity, the posttest 17HPROG level in serum has a sensitivity of 89% (cut-off value, 6.4 nmol/L), whereas in urine, the posttest aTHF level shows a sensitivity of 78% (cut-off value, 2.26 pmol/g creatinine), and the difference value of 17HPREG
shows a sensitivity of 72% (cut-off value 0.8 pmol/g creatinine).
The sum of both urinary parameters resulted in a sensitivity of 89% (cut-off value, 2.8 kmol/g creatinine).
Additionally, correlations between the urinary steroid metabolites were determined.
In the patient group, there were significant positive correlations between the following posttest parameters: 17HPREG correlates with THE, THF, CORT, /3CORT, ADT, ET, and PT; and PT correlates with CORT, PCORT, THE, THF, ET, and ADT. The respective P values varied between less than O.OOl(l7HPREG US. PT or PT US. ET) and 0.013 (17HPREG VS. CORT). No significant correlations were observed in the control group. of the posttest levels of aTHF (a; 11, the difference values of 17HPREG (b; 2), and the combination of both (c; 1 + 2) in urine of PCOS patients and controls undergoing nafarelin testing. The box and whisker plot presentation shows themedian, 25-75s range, and extremes (without outliers). Significant differences between PCOS and controls are indicated: *, P; 0.05; **, P < 0.01; ***, P < 0.001.
The serum and urine test parameters described above were not significantly different in lean and obese PCOS subjects.
Discussion
The use of basal hormone levels, LH/FSH ratios, elevated androgen levels, or pelvic ultrasound examinations often fail to give reliable diagnostic indications for PCOS. The nafarelin test, developed by Barnes ef al. (6), was the first test to assess suitable biochemical criteria for the diagnosis. The GnRHa nafarelin is a potent specific stimulator of the pituitary-gonadal axis; given as a single dose, it is much more potent than the commonly used GnRH. A short term stimulation test using this drug appears to be a useful tool in distinguishing PCOS from other causes of hyperandrogenism in women (7). Our study, using an intranasal application with pharmacodynamically equivalent doses, has confirmed these data concerning levels of 17HPROG and the gonadotropins in serum. In addition, we were able to document significant changes in urinary steroid metabolite levels, especially in those of androgens, gestagens, and corticoids.
In accordance with the data described by Barnes et al. (6), we found that the maximal gonadotropin responses in serum occurred after 4 h, whereas the ovarian steroid responses continued to rise during the entire 24-h test period. The LH/FSH ratio was clearly elevated in the patients at 24 h, as expected for this disorder. The most distinctive increase was that found for 17HPROG. In contrast to the findings of Barnes et al. (6), we observed no significant change in A in either the PCOS patients or controls, although the respective levels were higher in the patient group throughout.
In contrast T together with A, a product of the P45Oc17o enzyme complex, was found to be elevated in the PCOS patients compared to control levels and underwent a significant increase during the test in the patients. Of the T metabolites ADG and ADTG, only ADG significantly increased during the test in the PCOS patients. The observation that the concentration of ADTG remained unchanged in PCOS patients together with a marginally elevated T level can be explained by the fact that in our patient group the androgen excess was only moderate and the mean Ferriman-Gallwey index for the group of 19 patients was 7.5. Serum DHEAS, the main adrenal androgen parameter, showed no changes during the test in either group. The E, response to nafarelin was exaggerated in PCOS patients compared to the controls. These data give rise to the suggestion that cytochrome P450c17a may be dysregulated in the PCOS patients. Nevertheless, with regard to the serum T concentrations of the affected patients, increased activities of both the ovarian 17cy-hydroxylase and 17,20-lyase enzymes in the A4-steroid pathway cannot be ruled out. In addition to the diagnostic discrimination afforded by baseline parameters such as 17HPROG (with a sensitivity of 78% at 93% specificity; cutoff value, 2.5 nmol/L), only the posttest serum levels of 17HPROG allow a further distinction to be drawn between PCOS patients and controls with a sensitivity of 89% at 93% specificity (cut-off value, 6.4 nmol/L).
Applying the high resolution GC technique using the MSTFA derivatization method to the urine samples, we were able to quantify the abnormal steroidogenic response to nafarelin in the affected patients. The examination of the respective steroid profiles in the test subjects revealed a quite different pattern in the PCOS patients compared to the controls. In healthy women, only 17HPREG, the urinary derivative of 17HPROG, showed an significant increase during the test. In patients, however, there was a significant increase in the urinary metabolites of androgens (ADT and ET), gestagens (17HPREG, PD, and PT), and glucocorticoids (THE, THF, aTHF, CORT, pCORT, and F).
In our study, the urinary steroid profiles revealed greater 5aTHF/5PTHF
and ADT/ET ratios in PCOS patients (Fig. 4) . This is in accordance with the report of The box and whisker plot presentation shows the median, 25-75% range, and extremes (without outliers). Significant differences between PCOS and controls are indicated: *, P < 0.05; **, P < 0.01; ***, P < 0.001. skin of patients suffering from this endocrine disorder. In the course of the nafarelin test, however, only the aTHF/THFratio is altered, due to an increase in aTHF levels; the origin of this increased 5Lu-reductase activity level in PCOS is still under debate. According to Rosenfield (42), the overproduction of ovarian androgens seems to result in a stimulation of this enzyme in skin and liver (12,131. The borderline change in aTHF secretion in urine that was observed (P = 0.07) also suggests that the enhanced 5a-reductase activity may be the result of androgen excess and not due to a primary mechanism, as reported by Stewart et al. (14) .
According to Giagulli et al. (12) , ADG appears to be a better parameter for determining peripheral 5cY-reductase activity than ADT. Therefore, it would be necessary to determine the levels of urinary androstanediol, rather than ADT, to confirm our model. This, however, was not possible with the GC technique applied in this study due to peak interferences. It can be stated that the basal serum F level and basal free F level in urine are slightly elevated in PCOS patients compared with those in controls. This may be due to a preexisting alteration in adrenal corticoid secretion. Invitti et al. (33) documented an increased urinary free F level in PCOS patients and suggested that an overactive hypothalamic-pituitary-adrenal axis might be responsible. Rodin et al. (15) reported increased adrenal secretion of F due to an augmented adrenocortical activity in women with PCOS, but decreased urinary free F levels. The exaggerated glucocorticoid excretion in PCOS patients after naferelin treatment, however, is surprising and could be explained by an increased oxidation of F to E due to a dysregulated llPHSDH, which is not accounted for by obesity. As a result of the enhanced F clearance rate, the synthesis of adrenal androgens is augmented. In our study, the THE/THF ratio was significantly higher in PCOS patients us. controls at baseline (P < 0.05), which is in agreement with the ratio of the ll-oxo/ll-hydroxy metabolites of F reported by Rodin et al. (15) . In the course of the test, however, the PCOS patients showed a decrease in this ratio, which results in a loss of significance in the differences between the ratios in PCOS and control subjects. Therefore, it can be suggested that the abnormal 1lPHSDH activity is attenuated in the course of the GnRHa test. Due to a reduced conversion of F to E, the excretion of the respective F and corticosterone metabolites increases acutely over the 24-h test period. Our hypothesis is that the excess production of E, released by the gonadotropin surge in PCOS patients us. controls is able to attenuate the 1lPHSDH activity. Together with an increased metabolism of 17HPROG toward PT, this would explain the increased corticoid excretion in urine and the absence of a parallel increase in A and T in relation to 17HPROG in serum during the GnRHa test. Another possible explanation for the enhanced glucocorticoid excretion in PCOS patients after nafarelin application is that the gestagen surge that results from GnRHa stimulation displaces serum F from corticosteroidbinding globulin and leads to an augmented F metabolism. It has previously been described that serum corticosteroidbinding globulin levels are significantly decreased in PCOS patients (33).
Therefore, our data suggest that an altered interconversion of F and E is able to play a role in PCOS, as suggested for the augmented/dysregulated ovarian cytochrome P450c17a activity. The proportion and importance of the proposed enzyme dysregulation in the pathogenesis of PCOS have yet to be proven, because measurements of basal serum levels of 11-hydroxyandrostenedione, a marker of adrenal androgen secretion, support the idea that the ovaries and not the adrenals are the major source of androgens in PCOS (5). Additionally, divergent results concerning the elevation of DHEAS levels in PCOS patients have previously been described (22,23,43,44) and argue against a pivotal role of the adrenal glands in the etiology of this disorder. However, an altered sensitivity of the adrenal cortex to corticotropin, evidenced by higher ll-hydroxyandrostenedione levels after stimulation with corticotropin-releasing factor and an increased metabolic clearance of F and corticosterone, appears to be a supplementary symptom of the pathophysiological changes in PCOS.
One additional observation from our study is that, interestingly, in the PCOS patients, no significant differences in urinary steroid concentrations between the lean and obese patients could be found during the test. This would appear to rule out the idea that increased F production rates in obesity cause higher secretion rates of E in the adipose tissue of PCOS patients.
This study, undertaken with 19 PCOS patient and 15 controls, documents the efficiency of the nafarelin test in confirming the ovarian abnormality in PCOS suspected by the clinical diagnosis. The more practical intranasal application mode together with the measurements of urinary steroids gives an effective diagnostic tool for investigating this endocrine disorder. The study suggests that 17HPROG levels in serum together with those of aTHF and 17HPREG in urine are the best discriminatory parameters of the GnRHa stimulation test. An additional investigation concerning these three parameters should confirm our results by the application of confirmatory statistical analysis. The sensitivity of the test, as defined by the ability to detect an ovarian abnormality, was 89% for both the posttest level of 17HPROG in serum and the combination of the difference value of 17HPREG and the posttest value of aTHF in urine (all at a 93% specificity).
Further studies are necessary to determine whether a combination of the nafarelin stimulation test with, for example, short term dexamethasone suppression, is capable of distinguishing between the different forms of hyperandrogenism in women. Due to the variability of symptoms displayed by patients suffering from this endocrine disorder, additional investigation is required to confirm whether the suggested dysregulated enzyme systems, such as 11 PHSDH or cytochrome P45Oc17c~, are alone sufficient to cause PCOS or whether other ovarian and/or adrenal factors play a role in the pathogenesis. In addition, the reason for the exaggerated corticoid excretion in the course of the nafarelin stimulation is in need of clarification.
